Tesaro grants Zai Lab niraparib rights in China
Tesaro Inc. granted ZAI Lab Ltd. exclusive rights to develop and sell the cancer candidate niraparib in China. (Tesaro retains a co-promotion option.)
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.